PDL BioPharma, Inc. (PDLI) said Tuesday that it expects fourth quarter revenue of about $57 million, as compared to $69 million in the fourth quarter of last year.
Analysts polled by Thomson Reuters currently expect the company to post revenue of $60.61 million for the fourth quarter.
Included in last year's fourth quarter results was the first of two installment payments of $12.5 million from Alexion. Also included in last year's fourth quarter results was a one-time $1.8 million payment from Genentech for the exercise of options to four additional antigens and extension of the option period for two antigens under its license agreement with PDL.
PDL plans to release its financial results for the fourth quarter in late February 2010.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.